

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
WO 2004/004467 A1

(51) International Patent Classification<sup>7</sup>: A21D 8/04, (74) Common Representative: NOVOZYMES A/S; Patents, C12N 9/20, 9/02, C11D 3/386 Krogshøjvej 36, DK-2880 Bagsværd (DK).

(21) International Application Number: PCT/DK2003/000460 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 2 July 2003 (02.07.2003)

(25) Filing Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data: PA 2002 01042 3 July 2002 (03.07.2002) DK

(71) Applicant (for all designated States except US): NOVOZYMES A/S [DK/DK]; Krogshøjvej 36, DK-2880 Bagsværd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BORCH, Kim [DK/DK]; Vandtårnsvej 18, DK-3460 Birkerød (DK). CHRISTIANSEN, Luise [DK/DK]; Sommerstedgade 11, 2.th., DK-1718 Copenhagen V (DK). JENSEN, Morten, Tovborg [DK/DK]; Bringebakken 11, DK-3500 Værløse (DK).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/004467 A1

(54) Title: TREATMENT OF DOUGH WITH A LIPOXYGENASE AND A LIPOLYTIC ENZYME

WO (57) Abstract: The addition of a lipoxygenase and a lipolytic enzyme active on polar lipids to a dough has a synergistic effect on the volume and/or crumb color of an edible product made by leavening and heating the dough, e.g. by baking or steaming.

## TREATMENT OF DOUGH WITH A LIPOXYGENASE AND A LIPOLYTIC ENZYME

## FIELD OF THE INVENTION

The present invention relates to a process for preparing an edible product by leavening and heating the dough, e.g. by baking or steaming. More particularly, it relates to such a 5 process for preparing a product with an increased volume and/or improved crumb color (whiteness).

## BACKGROUND OF THE INVENTION

In the preparation of edible products by leavening and heating a dough, it is generally desirable to increase the volume of the product and to improve the crumb color (make the 10 crumb whiter).

WO 9826057 and US 4567046 disclose the addition of a phospholipase to dough. JP 55153549A discloses addition of a lipase and a lipoxygenase to flour. WO 9953769 and WO 2002094123 disclose the addition of enzymes to dough.

## SUMMARY OF THE INVENTION

15 The inventors have found that the addition of a lipoxygenase and a lipolytic enzyme active on polar lipids to a dough has a synergistic effect on the volume and/or crumb color of an edible product made by leavening and heating the dough, e.g. by baking or steaming.

Accordingly, the invention provides a process for preparing an edible product, comprising adding a lipoxygenase and a lipolytic enzyme active on polar lipids to a dough, leavening, and heating the dough, wherein the lipoxygenase and the lipolytic enzyme are added in 20 amounts producing a synergistic effect on the volume of the edible product.

The invention also provides a composition for use in the process.

## DETAILED DESCRIPTION OF THE INVENTION

## Lipoxygenase

25 The lipoxygenase (EC 1.13.11.12) is an enzyme that catalyzes the oxygenation of poly-unsaturated fatty acids such as linoleic acid, linolenic acid and arachidonic acid, which contain a *cis,cis*-1,4-pentadiene unit and produces hydroperoxides of these fatty acids. The lipoxygenase of the invention is able to oxidize substrates containing a *cis-cis*-pentadienyl moiety. Thus, it may act on polyunsaturated fatty acids such as linoleic acid (18 carbon atoms, 30 2 double bonds), linolenic acid (18:3), arachidonic acid (20:4), eicosapentaenoic acid (EPA, 20:5) and/or docosahexaenoic acid (DHA, 22:6).

The lipoxygenase may be a 9-lipoxygenase with the ability to oxidize the double bond

between carbon atoms 9 and 10 in linoleic acid and linolenic acid, or it may be a 13-lipoxygenase with the ability to oxidize the double bond between carbon atoms 12 and 13 in linoleic acid and linolenic acid.

The lipoxygenase may be from animal, plant or microbial source. A plant lipoxygenase 5 may be from plants of the pulse family (*Fabaceae*), soybean (lipoxygenases 1, 2 and 3), cucumber, or barley. A microbial lipoxygenase may be from a yeast such as *Saccharomyces cerevisiae*, a thermophilic actinomycete such as *Thermoactinomyces vulgaris* or *Thermomyces*, e.g. *T. lanuginosus*, or from fungi.

A fungal lipoxygenase may be derived from *Ascomycota*, particularly *Ascomycota in-10 certae sedis* e.g. *Magnaporthe*aceae, such as *Gaeumannomyces* or *Magnaporthe*, or anamorphic *Magnaporthe*aceae such as *Pyricularia*, or alternatively anamorphic *Ascomycota* such as *Geotrichum*, e.g. *G. candidum*. The fungal lipoxygenase may be from *Gaeumannomyces graminis*, e.g. *G. graminis* var. *graminis*, *G. graminis* var. *avenae* or *G. graminis* var. *tritici*, (WO 0220730) or *Magnaporthe salvinii* (PCT/DK 02/00251). Also, a fungal lipoxygenase may 15 be from *Fusarium* such as *F. oxysporum* or *F. proliferatum*, or *Penicillium* sp.

The lipoxygenase may be used at a dosage of 0.01-10 mg of enzyme protein per kg of flour, particularly 0.1-5 mg/kg, e.g. 0.2-1 mg/kg.

#### Lipolytic enzyme active on polar lipids

The invention uses a lipolytic enzyme which is capable of hydrolyzing carboxylic ester 20 bonds in polar lipids such as phospholipids and/or galactolipids, i.e. having phospholipase and/or galactolipase activity. Thus, the lipolytic enzyme may have phospholipase A1 or A2 activity (EC 3.1.1.32 or 3.1.1.4), i.e. hydrolytic activity towards one or both carboxylic ester bonds in phospholipids such as lecithin. Further, the lipolytic enzyme may have galactolipase activity (EC 3.1.1.26), i.e. hydrolytic activity on carboxylic ester bonds in galactolipids such as DGDG 25 (digalactosyl diglyceride).

The lipolytic enzyme may or may not have lipase activity (activity on triglycerides, EC 3.1.1.3). It may have a higher activity on polar lipids than on triglycerides.

The lipolytic enzyme may be of animal origin, e.g. from pancreas, snake venom or bee venom, or it may be of microbial origin, e.g. from filamentous fungi, yeast or bacteria, such 30 as *Aspergillus* or *Fusarium*, e.g. *A. niger*, *A. oryzae* or *F. oxysporum*, e.g. the enzymes described in WO 9826057, WO 0200852. Also, the variants described in WO 0032758 may be used, e.g. a variant of *Thermomyces lanuginosus* lipase having phospholipase and/or galactolipase activity.

The lipolytic enzyme may be used at a dosage of 0.01-10 mg of enzyme protein per 35 kg of flour, particularly 0.1-5 mg/kg, e.g. 0.2-1 mg/kg.

**Synergistic effect**

The combination of the lipoxygenase and the lipolytic enzyme has a synergistic effect on volume and/or crumb color of an edible product made by leavening and heating the dough.

Synergy may be determined by making doughs or baked products with addition of the 5 two enzymes separately and in combination, and comparing the effects; synergy is indicated when the combination produces a better effect than each enzyme used separately.

The comparison may be made between the combination and each enzyme alone at double dosage (on the basis of enzyme protein or enzyme activity). Thus, synergy may be said to occur if the effect of 0.5 mg of enzyme A + 1.0 mg of enzyme B is greater than the effect 10 with 1.0 mg of enzyme A and also greater than the effect with 2.0 mg of enzyme B.

Alternatively, the comparison may be made with equal total enzyme dosages (as pure enzyme protein). If the effect with the combination is greater than with either enzyme alone, this may be taken as an indication of synergy. As an example, synergy may be said to occur if the effect of 0.5 mg of enzyme A + 1.0 mg of enzyme B is greater than with 1.5 mg of enzyme 15 A or B alone.

**Dough**

The dough is leavened e.g. by adding chemical leavening agents or yeast, usually *Saccharomyces cerevisiae* (baker's yeast).

The dough generally comprises wheat meal or wheat flour and/or other types of meal, 20 flour or starch such as corn flour, corn starch, rye meal, rye flour, oat flour, oat meal, sorghum meal, sorghum flour, rice flour, potato meal, potato flour or potato starch.

The dough may be fresh, frozen or par-baked.

The dough may be a laminated dough.

The dough may also comprise other conventional dough ingredients, e.g.: proteins, 25 such as milk powder and gluten; eggs (either whole eggs, egg yolks or egg whites); an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine; a sugar; a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate. The dough may comprise fat (triglyceride) such as granulated fat or shortening.

30 The dough may further comprise an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lyssolecithin.

**Edible product**

The process of the invention is used for preparing a an edible product by leavening and heating a dough, e.g. by baking or steaming. The product may be of a soft or a crisp character, either of a white, light or dark type. Examples are steamed or baked bread (in particular white, whole-meal or rye bread), typically in the form of loaves or rolls, French baguette-type bread, pita bread, tortillas, cakes, pancakes, biscuits, cookies, pie crusts, crisp bread, steamed bread, pizza and the like.

**Enzyme composition**

The invention provides a composition (e.g. a baking composition) comprising a lipoxygenase, a phospholipase and optionally an additional enzyme as described below.

The composition may be an enzyme preparation, e.g. in the form of a granulate or agglomerated powder. It may have a narrow particle size distribution with more than 95 % (by weight) of the particles in the range from 25 to 500  $\mu\text{m}$ . Granulates and agglomerated powders may be prepared by conventional methods, e.g. by spraying the amylase onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size.

The carrier may be soluble or insoluble, e.g. a salt (such as NaCl or sodium sulfate), a sugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy.

The composition may, in addition to enzymes, comprise other baking ingredients, particularly flour. Thus, the composition may be a dough or a flour pre-mix.

**20 Additional enzyme**

Optionally, an additional enzyme may be used together with the lipoxygenase and the lipolytic enzyme.

The additional enzyme may be an amylase, a cyclodextrin glucanotransferase, a protease or peptidase, in particular an exopeptidase, a transglutaminase, a lipase, a phospholipase, a cellulase, a hemicellulase, a glycosyltransferase, a branching enzyme (1,4- $\alpha$ -glucan branching enzyme) or a second oxidoreductase. The additional enzyme may be of any origin, including mammalian and plant, and preferably of microbial (bacterial, yeast or fungal) origin.

The amylase may be from a fungus, bacterium or plant. It may be a maltogenic alpha-amylase (EC 3.2.1.133), e.g. from *B. stearothermophilus*, an alpha-amylase, e.g. from *Bacillus*, particularly *B. licheniformis* or *B. amyloliquefaciens*, a beta-amylase, e.g. from plant (e.g. soy bean) or from microbial sources (e.g. *Bacillus*), a glucoamylase, e.g. from *A. niger*, or a fungal alpha-amylase, e.g. from *A. oryzae*.

The hemicellulase may be a pentosanase, e.g. a xylanase which may be of microbial origin, e.g. derived from a bacterium or fungus, such as a strain of *Aspergillus*, in particular of *A.*

*aculeatus*, *A. niger*, *A. awamori*, or *A. tubigensis*, from a strain of *Trichoderma*, e.g. *T. reesei*, or from a strain of *Humicola*, e.g. *H. insolens*.

The protease may be from *Bacillus*, e.g. *B. amyloliquefaciens*.

The second oxidoreductase may be a glucose oxidase, a hexose oxidase, a peroxidase, or a laccase.

## EXAMPLES

### Example 1

1 kg flour doughs were prepared by a straight dough procedure with addition of phospholipase from *F. oxysporum* and lipoxygenase (LOX) from *M. salvinii* as shown in the table 10 below. The LU activity unit is defined in WO 0032758.

The doughs were leavened and baked, and the specific volume and crumb properties were evaluated for bread baked from each dough. Crumb properties were evaluated by a panel using a scale from 0 to 10 taking the control as 5, as follows:

Uniform: 0=uneven, 10=very uniform

15 Grain: 0=open, 10=fine

Cell wall: 0=thick, 10=thin

Cell form: 0=round, 10=elongate

Crumb color: 0=dark, 10=white

	Invention	Control	Reference		
<b>Phospholipase, LU/kg</b>	500		500		
<b>LOX, mg/kg</b>	0.2			0.2	
<b>Soy flour, % by weight</b>					0.5
<b>Sp. Vol. (ml/g)</b>	5.06	4.31	4.78	4.45	4.36
<b>Sp. Vol. (%)</b>	117	100	111	103	101
<b>Crumb evaluation (Ext. proof)</b>					
<b>Uniform</b>	7	5	7	3	4
<b>Grain</b>	7	5	7	2	4
<b>Cell Wall</b>	7	5	7	4	4
<b>Cell Form</b>	7	5	7	2	6
<b>Crumb Color</b>	7	5	6	6	8

The results show that soy flour has no impact on volume, but the crumb color (whiteness) is improved by soy flour.

5 LOX alone has no impact on volume, and the crumb color is slightly improved compared to the control.

The phospholipase alone gives clear volume and crumb structure improvements

LOX in combination with the lipase has a synergistic effect on volume, and crumb color is also improved compared to the phospholipase or LOX alone.

**CLAIMS**

1. A process for preparing an edible product, comprising adding a lipoxygenase and a lipolytic enzyme active on polar lipids to a dough, leavening, and heating the dough, wherein the lipoxygenase and the lipolytic enzyme are added in amounts producing a synergistic effect on the volume of the edible product.
2. A process of preparing a baked product comprising:
  - a) adding to a dough a lipoxygenase and a lipolytic enzyme active on polar lipids, and
  - b) baking the dough,wherein the lipoxygenase and the lipolytic enzyme are added in amounts producing a synergistic effect on the volume or the crumb color of the baked product.
3. A composition comprising: a lipoxygenase and a lipolytic enzyme active on polar lipids wherein the lipoxygenase and the lipolytic enzyme are added in amounts producing a synergistic effect on the volume or the crumb color of the baked product.
4. The composition of the preceding claim which further comprises flour.
- 15 5. The composition of the preceding claim which is a dough, a flour composition, or a flour pre-mix.
6. A method of increasing the volume or the crumb color of a baked product comprising:
  - a) adding to a dough a lipoxygenase and a lipolytic enzyme which is active on polar lipids and on triglycerides,
  - b) baking the dough to prepare a baked product, and
  - c) measuring the volume or the crumb color of the baked product.

## INTERNATIONAL SEARCH REPORT

International	Classification No
PCT/DK 03/00460	

A. CLASSIFICATION OF SUBJECT MATTER			
IPC 7	A21D8/04	C12N9/20	C12N9/02
			C11D3/386

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7	A21D	C12N	C11D
-------	------	------	------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, MEDLINE, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02 19828 A (NOVOZYMES AS) 14 March 2002 (2002-03-14) claim 8 ---	1-6
P,A	WO 02 086114 A (NOVOZYMES AS ;TAKAGI SHINOBU (JP); SUGIO AKIKO (US)) 31 October 2002 (2002-10-31) claim 11 ---	1-6
Y	T. GALLIARD: "Hydrolytic and Oxidative Degradation of Lipids During Storage of Wholemeal Flour: Effects of Bran and Germ Components " JOURNAL OF CEREAL SCIENCE, vol. 4, 1986, pages 179-192, XP002255190 figures 1-6 ---	1-6 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the International search

22 September 2003

Date of mailing of the international search report

05.11.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

FERNANDO FARIETA / ELY

## INTERNATIONAL SEARCH REPORT

Internati	Application No
PCT/DK 03/09460	

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI            Section Ch, Week 198106            Derwent Publications Ltd., London, GB;            Class D11, AN 1981-08437D            XP002255191            &amp; JP 55 153549 A (MEIJI SEIKA KAISHA ET            AL), 29 November 1980 (1980-11-29)            abstract</p> <p>---</p>	1-6
A	<p>WO 02 03805 A (CHRISTENSEN LUISE ;SPENDLER            TINA (DK); BUDOLFSEN GITTE (DK); NOVOZ)            17 January 2002 (2002-01-17)            claims 1-14</p> <p>---</p>	1-6
A	<p>WO 00 32758 A (SHAMKANT ANANT PATKAR            ;BORCH KIM (DK); PETRI ANDREAS (DK); VIND            JE) 8 June 2000 (2000-06-08)            claim 64</p> <p>-----</p>	1-6

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 03/00460

**Box 1 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 1-5 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 1-5

Present claims 1-5 relate to processes and compositions defined by reference to a desirable characteristic or property, namely "to be added in amounts producing a synergistic effect".

The claims cover all processes and compositions having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such processes and compositions. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the processes and compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the processes and compositions prepared in example 1.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No	PCT/DK 03/00460
------------------------------	-----------------

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0219828	A 14-03-2002	AU 8381701 A		22-03-2002
		WO 0219828 A1		14-03-2002
		US 2002094367 A1		18-07-2002
WO 02086114	A 31-10-2002	WO 02086114 A1		31-10-2002
JP 55153549	A 29-11-1980	JP 1379703 C		28-05-1987
		JP 61047492 B		20-10-1986
WO 0203805	A 17-01-2002	AU 7235901 A		21-01-2002
		CA 2412533 A1		17-01-2002
		WO 0203805 A1		17-01-2002
		EP 1301080 A1		16-04-2003
WO 0032758	A 08-06-2000	AU 1376300 A		19-06-2000
		BR 9915711 A		21-08-2001
		CA 2353379 A1		08-06-2000
		CN 1331742 T		16-01-2002
		WO 0032758 A1		08-06-2000
		EP 1131416 A1		12-09-2001
		JP 2003524386 T		19-08-2003
		NZ 511340 A		25-07-2003
		TR 200101497 T2		21-11-2001
		ZA 200102858 A		12-11-2001